Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for hepatitis B virus infection

R P Perrillo1, A L Mason

  • 1Section of Gastroenterology and Hepatology, Ochsner Clinic, New Orleans, Louisiana.

Gastroenterology Clinics of North America
|September 1, 1994
PubMed
Summary

Recombinant interferon alfa therapy for chronic hepatitis B shows a 40-50% initial response rate, with sustained viral loss and histological improvement. Patient selection is key for maximizing safety and efficacy of this hepatitis B treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systematic review: recurrent autoimmune liver diseases after liver transplantation.

Alimentary pharmacology & therapeutics·2016
Same author

Editorial: Betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease - authors' reply.

Alimentary pharmacology & therapeutics·2015
Same author

Frequent proviral integration of the human betaretrovirus in biliary epithelium of patients with autoimmune and idiopathic liver disease.

Alimentary pharmacology & therapeutics·2014
Same author

Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases.

Journal of viral hepatitis·2014
Same author

Letter: biochemical response to combination anti-retroviral therapy in patients with primary biliary cirrhosis.

Alimentary pharmacology & therapeutics·2013
Same author

Viruses and diabetes: is there something sweet about hepatitis C infection?

Ochsner journal·2012

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic viral hepatitis B (HBV) therapy has seen significant advancements.
  • Large multicenter trials of recombinant interferon alfa have been published globally.

Purpose of the Study:

  • To review the efficacy and safety of interferon alfa in treating chronic hepatitis B.
  • To highlight the importance of quantitative viral markers and patient selection.

Main Methods:

  • Analysis of data from large, multicenter trials of recombinant interferon alfa.
  • Review of studies assessing viral replication (HBV DNA, HBeAg) and HBsAg clearance.
  • Evaluation of histological improvements and treatment outcomes.

Main Results:

  • Initial response rates to interferon alfa are approximately 40-50%.
  • Sustained loss of viral replication and histological improvement are observed.
  • HBsAg disappearance occurs in one-third of responders, increasing with follow-up.

Conclusions:

  • Interferon alfa is an effective treatment for chronic hepatitis B, offering sustained viral control and histological benefits.
  • Quantitative viral markers aid in predicting response and monitoring therapy.
  • Careful patient selection and consideration of adjunctive therapies are crucial for optimizing outcomes and safety.

Related Experiment Videos